基于RNA干扰的多功能纳米平台用于胶质瘤治疗。
Multifunctional nanoplatforms based on RNA interference for glioma treatment.
作者信息
Zhao Ting, Ju Hongping, Chen Zihao
机构信息
Department of Clinical Pharmacy, The First Affiliated Hospital of Kunming Medical University Kunming, Yunnan, PR China.
School of Medicine, Kunming University Kunming, Yunnan, PR China.
出版信息
Am J Cancer Res. 2025 Mar 15;15(3):835-854. doi: 10.62347/AERM5603. eCollection 2025.
Glioma is the most common malignant tumor in the central nervous system. Currently, common clinical treatments for glioma include surgery, radiation therapy, chemotherapy and immunotherapy, among which the combination of chemotherapy and immunotherapy has attracted wide attention. However, the ability of chemotherapeutic agents and immune checkpoint blockers to reach gliomas is limited due to the existence of blood brain/tumor barrier (BBB/BTB). RNA interference (RNAi) technology enables specific silencing of target genes associated with cancer therapy, so it has been used as an emerging potential cancer treatment strategy. However, Small interference RNA (siRNA) is easily degraded by serum endonuclease, which can be quickly filtered and cleared by the glomerulus. Therefore, design and construction of safe and effective delivery systems is conducive to improving the stability of siRNA and the efficiency of gene silencing. This review focuses on the research progress of nano delivery system based on RNA interference for glioma treatment.
胶质瘤是中枢神经系统中最常见的恶性肿瘤。目前，胶质瘤的常见临床治疗方法包括手术、放疗、化疗和免疫治疗，其中化疗与免疫治疗的联合应用备受关注。然而，由于血脑屏障/血肿瘤屏障（BBB/BTB）的存在，化疗药物和免疫检查点阻滞剂到达胶质瘤的能力有限。RNA干扰（RNAi）技术能够特异性沉默与癌症治疗相关的靶基因，因此已被用作一种新兴的潜在癌症治疗策略。然而，小干扰RNA（siRNA）容易被血清核酸酶降解，并且能够被肾小球快速滤过和清除。因此，设计和构建安全有效的递送系统有助于提高siRNA的稳定性和基因沉默效率。本综述重点关注基于RNA干扰的纳米递送系统用于胶质瘤治疗的研究进展。
Zotero 插件